Pharmaceutical company Amneal Pharmaceuticals (NASDAQ: AMRX) missed Wall Street’s revenue expectations in Q2 CY2025 as sales rose 3.2% year on year to $724.5 million. On the other hand, the company’s full-year revenue guidance of $3.05 billion at the midpoint came in 1.2% above analysts’ estimates. Its non-GAAP profit of $0.25 per share was 42.9% above analysts’ consensus estimates.

Is now the time to buy AMRX? Find out in our full research report (it’s free).

StockStory’s Take

Amneal’s second quarter results reflected a mixed performance, with revenue growth falling short of Wall Street expectations but profitability coming in notably ahead of analyst forecasts. Management highlighted strong execution within its specialty medicines segment, particularly the CREXONT launch for Parkinson’s disease and steady uptake across branded products. CFO Anastasios Konidaris pointed to "favorable product mix in each of the 3 segments and ongoing operating efficiencies" as key contributors to margin improvement, even as the company faced headwinds in its AvKARE distribution business.

Looking ahead, Amneal’s updated guidance is supported by anticipated new product launches, ongoing expansion in biosimilars, and the commercial rollout of the Brekiya autoinjector. Management believes these efforts, combined with operational investments and strategic collaborations such as the partnership with Metsera in the GLP-1 market, will help drive top-line growth and further diversify earnings. Co-CEO Chirag K. Patel emphasized, "We are entering our next phase of growth with strong momentum and clear confidence in growth ahead," while noting that execution on upcoming launches and manufacturing enhancements remain critical to achieving these targets.

Key Insights from Management’s Remarks

Management attributed the quarter’s margin expansion and profitability to strong specialty product uptake, operational investments, and progress in biosimilars and new launches.

• Specialty segment momentum: CREXONT for Parkinson’s disease exceeded internal expectations in its first year, capturing about 2% U.S. market share and projected to surpass 3% by year-end. Management cited robust payor coverage and strong prescriber feedback as supporting ongoing growth.
• Brekiya autoinjector launch: The upcoming October launch of Brekiya, an autoinjector for migraine treatment, is positioned as a first-in-class option for patients not responding to existing therapies. Management views this as a $50–$100 million peak sales opportunity.
• GLP-1 market expansion: Amneal’s partnership with Metsera is progressing, with two new manufacturing facilities being built to support high-value peptide production for obesity therapies. Management expects significant revenue opportunities in both developed and emerging markets, particularly India.
• Affordable Medicines pipeline: The company launched 15 new generic products in the first half of the year, with a continued cadence of 20–30 launches expected annually. These include complex injectables and pending approvals in ophthalmics and inhalation therapies starting in 2026.
• Biosimilars progress: Amneal is advancing five biosimilar candidates with filings and launches targeted for 2026–2027. The biosimilar XOLAIR program recently reported positive Phase III data, with management aiming for a leadership position as more biologic patents expire.

Drivers of Future Performance

Amneal’s outlook is underpinned by new specialty launches, biosimilar expansion, and operational leverage, though generic competition and regulatory risks remain key variables.

• Specialty product launches: Management expects the continued growth of CREXONT and the commercial introduction of Brekiya to drive specialty revenues. CREXONT’s uptake, supported by increasing payor coverage, is expected to partially offset anticipated headwinds from RYTARY’s loss of exclusivity.
• Biosimilar and pipeline expansion: The company is targeting multiple biosimilar filings and launches through 2027. Management believes the increasing number of biologic patent expirations, combined with Amneal’s investments in manufacturing and R&D, will create meaningful long-term revenue streams—though execution risk and regulatory timelines remain important considerations.
• GLP-1 and international growth: The partnership with Metsera positions Amneal to participate in the expanding GLP-1 market for obesity, particularly in India and other emerging markets. Management sees this as a substantial growth driver, but notes that pricing and competitive dynamics could impact profitability as these therapies scale.

Catalysts in Upcoming Quarters

In upcoming quarters, our team will watch (1) the pace and breadth of new specialty product launches—especially Brekiya and additional generics, (2) execution on biosimilar filings and advancement of the XOLAIR program, and (3) progress on the Metsera GLP-1 collaboration and manufacturing ramp. Progress on U.S. and international expansion, as well as tariff policy developments, will be additional factors influencing Amneal’s outlook.

Amneal currently trades at $9.03, up from $7.98 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free).

Now Could Be The Perfect Time To Invest In These Stocks

Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.

The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.